DORIVAN

This brand name is authorized in Nigeria.

Active ingredients

The drug DORIVAN contains one active pharmaceutical ingredient (API):

1	Diclofenac UNII L4D5UA6CB4 - DICLOFENAC POTASSIUM
	Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms.
	Read more about Diclofenac

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-2631	Tablet	Dorivan 50 Tablet TAB 50 mg 1 x 10's (in blister)	Each tablet contains: Diclofenac Potassium 50 mg. Excipients (mg): Maize Starch 224.415, Lactose 155.640, Dibasic calcium phosphate 150.450, Maize Starch (Paste) 20.755, P.V.P.K 30 5.190, Methyl Paraben 0.519, Propyl Paraben 0.051, Cellulose Acetate Phthalate 0.500, Purified Talc 1.500, Magnesium Stearate7.500, Sodium Lauryl Sulphate 5.000, Cross Croscarmellose sodium 16.000, Colloidal Silicon Dioxide 5.000, COATING – Isopropyl Alcohol 13.950(kg), Methylene Chloride 13.950(kg), Hydroxy Propyl Methyl Cellulose 11.63	30/04/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M01AB05	Diclofenac	M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AB Acetic acid derivatives and related substances
Discover more medicines within M01AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-2631